<VariationArchive RecordType="classified" VariationID="55918" VariationName="NM_001482.3(GATM):c.1111dup (p.Met371fs)" VariationType="Duplication" Accession="VCV000055918" Version="4" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2022-11-19" DateCreated="2015-12-21" MostRecentSubmission="2022-11-13">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="70560" VariationID="55918">
      <GeneList>
        <Gene Symbol="GATM" FullName="glycine amidinotransferase" GeneID="2628" HGNC_ID="HGNC:4175" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>15q21.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="45361124" stop="45402227" display_start="45361124" display_stop="45402227" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="45653321" stop="45670979" display_start="45653321" display_stop="45670979" Strand="-" />
          </Location>
          <OMIM>602360</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_001482.3(GATM):c.1111dup (p.Met371fs)</Name>
      <CanonicalSPDI>NC_000015.10:45363947:T:TT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>15q21.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="45363947" stop="45363948" display_start="45363947" display_stop="45363948" variantLength="1" positionVCF="45363947" referenceAlleleVCF="A" alternateAlleleVCF="AT" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="45656145" stop="45656146" display_start="45656145" display_stop="45656146" variantLength="1" positionVCF="45656145" referenceAlleleVCF="A" alternateAlleleVCF="AT" />
      </Location>
      <OtherNameList>
        <Name>NM_001482.3(GATM):c.1111dup</Name>
        <Name>p.Met371fs</Name>
      </OtherNameList>
      <ProteinChange>M371fs</ProteinChange>
      <ProteinChange>M242fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.10" sequenceAccession="NC_000015" sequenceVersion="10" change="g.45363948dup" Assembly="GRCh38">
            <Expression>NC_000015.10:g.45363948dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.9" sequenceAccession="NC_000015" sequenceVersion="9" change="g.45656146dup" Assembly="GRCh37">
            <Expression>NC_000015.9:g.45656146dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011674.2" sequenceAccession="NG_011674" sequenceVersion="2" change="g.43370dup">
            <Expression>NG_011674.2:g.43370dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001321015.2" sequenceAccession="NM_001321015" sequenceVersion="2" change="c.724dup">
            <Expression>NM_001321015.2:c.724dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001307944.1" sequenceAccession="NP_001307944" sequenceVersion="1" change="p.Met242fs">
            <Expression>NP_001307944.1:p.Met242fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001482.3" sequenceAccession="NM_001482" sequenceVersion="3" change="c.1111dup" MANESelect="true">
            <Expression>NM_001482.3:c.1111dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001473.1" sequenceAccession="NP_001473" sequenceVersion="1" change="p.Met371fs">
            <Expression>NP_001473.1:p.Met371fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="602360.0002" DB="OMIM" />
        <XRef Type="rs" ID="397515542" DB="dbSNP" />
        <XRef ID="CA344713" DB="ClinGen" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_001482.3(GATM):c.1111dup (p.Met371fs) AND Arginine:glycine amidinotransferase deficiency" Accession="RCV000049331" Version="10">
        <ClassifiedConditionList TraitSetID="1986">
          <ClassifiedCondition DB="MedGen" ID="C2675179">Arginine:glycine amidinotransferase deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>reviewed by expert panel</ReviewStatus>
            <Description DateLastEvaluated="2022-06-06" SubmissionCount="3">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-06-06" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2015-12-21" MostRecentSubmission="2022-11-13">
        <ReviewStatus>reviewed by expert panel</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">20682460</ID>
        </Citation>
        <Citation Type="general">
          <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/1ad7be29-ad14-4f7a-9207-e9e7ac4cc6d9</URL>
        </Citation>
        <Citation Type="review" Abbrev="GeneReviews">
          <ID Source="PubMed">20301745</ID>
          <ID Source="BookShelf">NBK3794</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1986" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4606" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">L-Arginine:Glycine Amidinotransferase Deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">AGAT deficiency</ElementValue>
                <XRef ID="AGAT+Deficiency/261" DB="Genetic Alliance" />
                <XRef ID="MONDO:0012996" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Arginine:glycine amidinotransferase deficiency</ElementValue>
                <XRef ID="702440000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cerebral creatine deficiency syndrome 3</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Creatine deficiency syndrome due to AGAT deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GATM deficiency</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CCDS3</ElementValue>
                <XRef Type="MIM" ID="612718" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10323" />
                <XRef ID="10323" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The creatine deficiency disorders (CDDs), inborn errors of creatine metabolism and transport, comprise three disorders: the creatine biosynthesis disorders guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency; and creatine transporter (CRTR) deficiency. Developmental delay and cognitive dysfunction or intellectual disability and speech-language disorder are common to all three CDDs. Onset of clinical manifestations of GAMT deficiency (reported in ~130 individuals) is between ages three months and two years; in addition to developmental delays, the majority of individuals have epilepsy and develop a behavior disorder (e.g., hyperactivity, autism, or self-injurious behavior), and about 30% have movement disorder. AGAT deficiency has been reported in 16 individuals; none have had epilepsy or movement disorders. Clinical findings of CRTR deficiency in affected males (reported in ~130 individuals) in addition to developmental delays include epilepsy (variable seizure types and may be intractable) and behavior disorders (e.g., attention deficit and/or hyperactivity, autistic features, impulsivity, social anxiety), hypotonia, and (less commonly) a movement disorder. Poor weight gain with constipation and prolonged QTc on EKG have been reported. While mild-to-moderate intellectual disability is commonly observed up to age four years, the majority of adult males with CRTR deficiency have been reported to have severe intellectual disability. Females heterozygous for CRTR deficiency are typically either asymptomatic or have mild intellectual disability, although a more severe phenotype resembling the male phenotype has been reported.</Attribute>
                <XRef ID="NBK3794" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301745</ID>
                <ID Source="BookShelf">NBK3794</ID>
              </Citation>
              <XRef ID="35704" DB="Orphanet" />
              <XRef ID="C2675179" DB="MedGen" />
              <XRef ID="MONDO:0012996" DB="MONDO" />
              <XRef Type="MIM" ID="612718" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="131103" SubmissionDate="2020-06-11" DateLastUpdated="2020-06-15" DateCreated="2013-07-24">
        <ClinVarSubmissionID localKey="602360.0002_CEREBRAL CREATINE DEFICIENCY SYNDROME 3" title="GATM, 1-BP INS, 1111A_CEREBRAL CREATINE DEFICIENCY SYNDROME 3" />
        <ClinVarAccession Accession="SCV000081763" DateUpdated="2020-06-15" DateCreated="2013-07-24" Type="SCV" Version="4" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2010-10-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In 2 sibs, born of unrelated Yemenite Jewish parents, with cerebral creatine deficiency syndrome-3 (CCDS3; 612718), Edvardson et al. (2010) identified a homozygous 1-bp insertion (1111insA) in the GATM gene, resulting in a frameshift and premature termination at codon 376. Each unaffected parent was heterozygous for the mutation, which was not found in 57 ethnic controls. Both patients showed delayed psychomotor development in infancy with poor speech acquisition. Each also had symptoms of a myopathy, with easy fatigability and predominantly proximal muscle weakness and atrophy. Brain MRS showed decreased creatine, and urine guanidinoacetate levels were low. Treatment with oral creatine resulted in clinical improvement and increased cerebral creatine levels.</Attribute>
              <Citation>
                <ID Source="PubMed">20682460</ID>
              </Citation>
              <XRef DB="OMIM" ID="612718" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GATM" />
          </GeneList>
          <Name>GATM, 1-BP INS, 1111A</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP INS, 1111A</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="602360.0002" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">CEREBRAL CREATINE DEFICIENCY SYNDROME 3</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="145583" SubmissionDate="2015-12-10" DateLastUpdated="2022-10-01" DateCreated="2013-10-02">
        <ClinVarSubmissionID localKey="NM_001482.2:c.1111dupA|OMIM:612718" />
        <ClinVarAccession Accession="SCV000086847" DateUpdated="2022-10-01" DateCreated="2013-10-02" Type="SCV" Version="3" SubmitterName="GeneReviews" OrgID="500062" OrganizationCategory="resource" OrgAbbreviation="GeneReviews" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no classification provided</ReviewStatus>
          <GermlineClassification>not provided</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20682460</ID>
          </Citation>
          <Citation>
            <ID Source="BookShelf">NBK3794</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GATM" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NP_001473.1:p.Met371AsnfsTer6</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001482.2:c.1111dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C2675179" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11808016</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion FDARecognizedDatabase="true" ID="5080788" SubmissionDate="2022-11-09" DateLastUpdated="2022-11-13" DateCreated="2022-11-13">
        <ClinVarSubmissionID localKey="1ad7be29-ad14-4f7a-9207-e9e7ac4cc6d9" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV002600079" DateUpdated="2022-11-13" DateCreated="2022-11-13" Type="SCV" Version="1" SubmitterName="ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel, ClinGen" OrgID="508816" OrganizationCategory="consortium" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-06">
          <ReviewStatus>reviewed by expert panel</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/1ad7be29-ad14-4f7a-9207-e9e7ac4cc6d9</URL>
          </Citation>
          <Comment>The NM_001482.3:c.1111dup (p.Met371AsnfsTer6) variant in GATM is a frameshift variant predicted to cause a premature stop codon in the last 50 nucleotides of the penultimate exon and therefore to escape nonsense mediated decay. More than 10% of the protein is predicted to be removed (PVS1_Strong). This variant has been detected in two siblings with AGAT deficiency who had significantly decreased creatine peak on brain MRS (PMID 20682460) (PP4_Strong). Both individuals were homozygous for the variant, confirmed in trans by parental testing (PMID 20682460) (PM3_Supporting). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). In summary, this variant meets the criteria to be classified as pathogenic for AGAT deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.1.0): PVS1_Strong, PP4_Strong, PM3_Supporting, PM2_Supporting. (Classification approved by the ClinGen CCDS VCEP on June 6, 2022).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ClinGen_CCDS_ACMG_Specifications_GATM_v1.1</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/4jbpw7f6/clingen_ccds_acmg_specifications_gatm_v1.1.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GATM" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_001482.3(GATM):c.1111dup</Name>
            <Name>p.Met371fs</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000015.10:g.45363948dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0012996" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12271247</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5080788" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0012996" MappingRef="MONDO">
        <MedGen CUI="C2675179" Name="Arginine:glycine amidinotransferase deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="145583" TraitType="Disease" MappingType="XRef" MappingValue="C2675179" MappingRef="MedGen">
        <MedGen CUI="C2675179" Name="Arginine:glycine amidinotransferase deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="131103" TraitType="Disease" MappingType="Name" MappingValue="CEREBRAL CREATINE DEFICIENCY SYNDROME 3" MappingRef="Preferred">
        <MedGen CUI="C2675179" Name="Arginine:glycine amidinotransferase deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

